LYZZ Capital — Full Portfolio
14 tracked investments · listed companies and verified rows first
Allotera develops allogeneic (off-the-shelf) CAR-T cell therapies targeting T-cell cancers such as T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, and T-cell non-Hodgkin's lymphoma, as well as autoimmune indications.
BiotechHealthtechSt. Louis, US
Co-investorsAisling CapitalBioGenerator VenturesRiverVest Venture PartnersAbingworth
A biopharmaceutical company developing oncology treatments including EGFR-targeting small molecule drugs for lung cancer with CNS penetration, and expanding into cell immunotherapy through licensed partnerships for NK cell and CAR-T therapies targeting solid tumors and hematologic malignancies.
BiotechDeep TechHealthtechMedical DevicesShanghai, CN
Xian-ping LU(Founder)in
Co-investorsCowin Capital GroupEFung CapitalLAVLilly Asia VenturesVertex Ventures China
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
David Michael Salter(Executive Officer, Director)Mike Salter(CEO/President)inEugene Chen(Director)Keith Brown(Executive Officer, Director)Joel Rotroff(Director)
BoardCourt Turner(Director)
Co-investorsArboretum VenturesBaird CapitalGlobal Health Investment Corporation
MicroTech Medical provides medical information services in China, with operational headquarters in Hangzhou and a principal place of business in Hong Kong.
Digital HealthHardwareMedical DevicesHangzhou, CN
Mark Dore(Founder)Pan Zheng(Founder)
Co-investorsLAVLilly Asia VenturesQiming Venture Partners
Mojiabio produces Aliphane, a bio-based chemical ingredient used in adhesives for applications including wood furniture, footwear, flexible packaging, automotive, and EV batteries.
AgTechBiotechCleantechNew Materials
Indra Jones Santanain
Co-investorsBits x Bites
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsHBM Healthcare InvestmentsHBM PartnersOrbiMed
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsXeraya CapitalB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment Partners+1 more
QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria.
BiotechHealthtechSan Diego, US
Michael N. Dudley(Executive Officer, Director)inTerry Gould(Director)Daniel Burgess(Director)
BoardCarol Gallagher(Director)inDouglas Reed(Director)inKevin Li(Director)in
Co-investorsHatteras Venture PartnersNew Enterprise Associates (NEA)Adams Street Partners
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity Investments
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
WxyuannuoYun300Zhiyunyilu
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
















.jpeg)










